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Blockade of checkpoint inhibitors has recently shown very convincing results in the 
treatment of cancer. One key target is CTLA-4, which has been demonstrated to be a 
potent negative regulator of lymphocyte activation. The treatment with the FDA-
approved fully human CTLA-4 monoclonal antibody Ipilimumab increases anticancer 
T-cell reactivity and overall survival of metastatic cancer patients. Indole-amine 2,3-
dioxygenase (IDO) is another checkpoint inhibitor which suppresses T-cell immunity 
by the depletion of tryptophan in the T-cell microenvironment, and also inhibition of 
IDO by L-1-Methyltryptophan (L-1MT) has shown promising results in clinical phase 
I/II studies of human cancer such as epithelial ovarian cancer. 
Pre-clinical immune therapeutic studies are usually performed with mice, but 
Ipilimumab is not reactive with mouse cells. Recent studies indicate that the pig may 
be a more suitable animal model for studies of immune reactivity due to higher 
similarity of the immunome between pig and man. This study is part of the 
CANVACPIG project “Accelerating development of vaccines against cancer with 
pigs as a large animal model” and investigates the reactivity of a fully human 
monoclonal anti CTLA-4 antibody and L-1MT on porcine immune cells. 
At the genome level, the homology between human and pig CTLA-4 and IDO is 86% 
and 73%, respectively, while the homology to the mouse is 75% and 63%. Our 
preliminary in vitro studies indicate that the monoclonal anti CTLA-4 antibody 
induces a non-specific activation of porcine T cells. This will be further investigated 
to provide the basis for in vivo studies investigating checkpoint inhibitor blockade in 
combination with other cancer immunotherapies. Eventually our goal is to establish 
pigs as an alternative large animal model for development and formulation of new 
human cancer vaccines. 
 
  
